Page 61 - 2020_11-Haematologica-web

Basic biology of acute GvHD
sion limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res. 2011;17(12):3969-3983.
64. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol. 2008;38(6):1654- 1663.
65. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of con- served non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010;463(7282):808-812.
66. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.
67.Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129-139.
68. Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat Immunol. 2014;15(6):580-587.
69. DuPage M, Chopra G, Quiros J, et al. The chromatin-modifying enzyme Ezh2 is criti- cal for the maintenance of regulatory T cell identity after activation. Immunity. 2015;42(2):227-238.
70.Goswami S, Apostolou I, Zhang J, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018;128(9):3813-3818.
71.Akimova T, Ge G, Golovina T, et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol. 2010;136(3): 348-363.
72. Wang L, Liu Y, Han R, et al. FOXP3+ regula- tory T cell development and function require histone/protein deacetylase 3. J Clin Invest. 2015;125(3):1111-1123.
73. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the genera- tion and function of regulatory T cells. Nat Med. 2007;13(11):1299-1307.
74. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform- specific mechanisms. Sci Signal. 2012;5(229):ra45.
75. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacte- ria promote peripheral regulatory T-cell gen- eration. Nature. 2013;504(7480):451-455.
76.Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regula- tory T cells. Nature. 2013;504(7480):446-
450.
77.Han L, Jin H, Zhou L, et al. Intestinal
Microbiota at engraftment influence acute graft-versus-host disease via the Treg/Th17 balance in allo-HSCT recipients. Front Immunol. 2018;9:669.
78. Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal Clostridia: lead- ing players in the maintenance of gut home- ostasis. Gut Pathog. 2013;5(1):23.
79. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone- deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2008;19(9):587-593.
80. Ranjan S, Goihl A, Kohli S, et al. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. Nat Commun. 2017;8(1):311.
81. Hanash AM, Dudakov JA, Hua G, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host dis- ease. Immunity. 2012;37(2):339-350.
82. Lindemans CA, Calafiore M, Mertelsmann AM, et al. Interleukin-22 promotes intestin- al-stem-cell-mediated epithelial regenera- tion. Nature. 2015;528(7583):560-564.
83. Takashima S, Kadowaki M, Aoyama K, et al. The Wnt agonist R-spondin1 regulates sys- temic graft-versus-host disease by protect- ing intestinal stem cells. J Exp Med. 2011;208(2):285-294.
84. Lopez-Arribillaga E, Rodilla V, Pellegrinet L, et al. Bmi1 regulates murine intestinal stem cell proliferation and self-renewal down- stream of Notch. Development. 2015;142(1): 41-50.
85. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet. 2008;40(7):915-920.
86. Cho JH, Dimri M, Dimri GP. A positive feed- back loop regulates the expression of poly- comb group protein BMI1 via WNT signal- ing pathway. J Biol Chem. 2013;288(5):3406- 3418.
87. Yeste A, Mascanfroni ID, Nadeau M, et al. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun. 2014;5:3753.
88. Lee SE, Lim JY, Ryu DB, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(10): 1933-1943.
89. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota fol- lowing allogeneic bone marrow transplanta- tion. J Exp Med. 2012;209(5):903-911.
90. Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites
modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016;17(5):505-513.
91. Wu SR, Reddy P. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood. 2017;129(13):1747-1752.
92. Choi SW, Braun T, Chang L, et al. Vorinostat plus tacrolimus and mycophenolate to pre- vent graft-versus-host disease after related- donor reduced-intensity conditioning allo- geneic haemopoietic stem-cell transplanta- tion: a phase 1/2 trial. Lancet Oncol. 2014;15(1):87-95.
93. Choi SW, Braun T, Henig I, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017;130(15): 1760-1767.
94. Perez L, Fernandez H, Horna P, et al. Phase I trial of histone deacetylase inhibitor panobi- nostat in addition to glucocorticoids for pri- mary therapy of acute graft-versus-host dis- ease. Bone Marrow Transplant. 2018;53(11): 1434-1444.
95. Ghobadi A, Fiala MA, Abboud CN, et al. A phase I study of azacitidine after donor lym- phocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplan- tation. Blood. 2013;122(21):3320-3320.
96.Schroeder T, Frobel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9): 1910-1913.
97. Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regula- tory T cells after allogeneic stem cell trans- plantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361- 3369.
98.
99.
Lübbert M, Bertz H, Ruter B, et al. Non- intensive treatment with low-dose 5-aza-2'- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44(9):585- 588.
Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(2):255-260.
100. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allo- geneic CD8+ T cells to elicit hepatic graft- versus-host disease. J Immunol. 2002;169 (12):7111-7118.
101.Dertschnig S, Evans P, Santos ESP, et al. Graft-versus-host disease reduces lymph node display of tissue-restricted self-anti- gens and promotes autoimmunity. J Clin Invest. 2020;130(4):1896-1911.
haematologica | 2020; 105(11)
2549